Fatty Liver

Our Approach to Managing Fatty Liver

Stage the disease. Address the cause. Reverse what's reversible.

The most important thing to understand about fatty liver disease is this: in its earliest stage, it is genuinely reversible. Simple steatosis - fat accumulation without significant inflammation or scarring - can resolve completely with appropriate lifestyle changes. But left unaddressed, this same condition can progress through NASH (non-alcoholic steatohepatitis) to fibrosis, and ultimately cirrhosis - a journey that, once advanced, cannot be reversed. The entire purpose of early diagnosis is catching patients while reversal is still possible.

At Shree Hospitals, our approach to NAFLD diagnosis and liver health management in Mumbai is built around accurate staging - distinguishing simple fatty liver from more advanced disease - because this distinction fundamentally changes both the urgency and the nature of the intervention required. Our hepatologist liver specialists ensure every patient understands exactly where they stand and what specific steps will protect their liver health.

1. Comprehensive Diagnostic Assessment

• Liver ultrasound - the initial screening tool, identifying fatty infiltration and assessing for any structural abnormality
• Liver function tests - ALT, AST, GGT, and bilirubin levels providing initial insight into liver inflammation and function
• Fibroscan and liver function assessment - a non-invasive elastography technique measuring liver stiffness, providing an accurate estimate of fibrosis stage without the need for biopsy
• Controlled Attenuation Parameter (CAP) score - measured alongside Fibroscan, quantifying the degree of fat content within the liver
• Metabolic workup - fasting glucose, HbA1c, lipid profile, and insulin resistance assessment, addressing the metabolic drivers underlying most fatty liver cases
• Exclusion of alternative liver disease causes - viral hepatitis screening, autoimmune markers, and iron studies as clinically indicated

2. Liver Biopsy for Selected Cases 

   While most patients are managed without biopsy, it remains valuable in specific circumstances:

• Liver biopsy reserved for cases with diagnostic uncertainty or discordant non-invasive test results
• Histological confirmation of NASH versus simple steatosis when this distinction significantly changes management urgency
• Liver fibrosis staging through histopathology providing the most definitive assessment when non-invasive tests are inconclusive
• Used selectively, recognising that most patients can be appropriately managed through non-invasive assessment alone

3. Metabolic Risk Factor Management

    

   Since fatty liver is fundamentally a metabolic condition, comprehensive risk factor management drives treatment:

• Structured weight loss programme - even a 7 to 10% reduction in body weight can significantly improve or resolve fatty liver and associated inflammation
• Diabetes management optimisation - tight glycaemic control directly benefits metabolic associated liver disease progression
• Lipid management - addressing dyslipidaemia as both a cardiovascular risk factor and contributor to liver fat accumulation
• Coordinated care with endocrinology and nutrition specialists for patients with complex metabolic syndrome

4. Lifestyle Intervention Programme
    
   

   The single most effective treatment for fatty liver disease at every stage:

• Structured dietary counselling - Mediterranean-pattern diet with reduced refined carbohydrate and saturated fat intake
• Supervised exercise programme - combining aerobic and resistance training, proven to reduce liver fat independent of weight loss alone
• Alcohol cessation counselling - even moderate alcohol intake can compound fatty liver progression and should be addressed
• Behavioural support and structured follow-up - recognising that sustainable lifestyle change requires ongoing support, not a single consultation

5. Pharmacological Management

    

   For patients with confirmed NASH or significant fibrosis:

• Vitamin E supplementation - evidence-supported benefit for selected non-diabetic patients with biopsy-confirmed NASH
• Pioglitazone - insulin-sensitising medication with demonstrated benefit in NASH management for appropriately selected patients
• GLP-1 receptor agonists - emerging evidence supporting benefit for weight loss and liver fat reduction in patients with associated diabetes or obesity
• Management of associated cardiovascular risk factors - recognising that cardiovascular disease, not liver failure, remains the leading cause of mortality in fatty liver patients

6. Long-Term Monitoring & Cirrhosis Prevention

• Structured liver fibrosis staging reassessment at defined intervals using Fibroscan, tracking response to treatment over time
• Surveillance for advanced fibrosis or cirrhosis development in higher-risk patients, including periodic imaging and blood marker assessment
• Hepatocellular carcinoma surveillance for patients who have progressed to cirrhosis, following established screening protocols
• Coordinated long-term care ensuring sustained lifestyle changes and metabolic optimisation as part of comprehensive Fatty Liver treatment in Mumbai, India